Pulse Biosciences (PLSE) EBIT Margin (2021 - 2025)
Pulse Biosciences' (PLSE) quarterly EBIT Margin came in at 23682.56% in Q3 2025, down 347.83% quarter-over-quarter from 5288.3% in Q2 2022.
Pulse Biosciences (PLSE) EBIT Margin (2021 - 2025) Analysis & Trends
Pulse Biosciences' EBIT Margin history runs 3 years deep, the most recent figure standing at 23682.56% for Q3 2025.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 23682.56% in Q3 2025; TTM through Sep 2025 was 91798.84%, a N/A change from a year earlier, with the FY2022 full-year figure at 8293.86%, down 379286.0% from the prior year.
- EBIT Margin declined to 23682.56% in Q3 2025 per PLSE's latest filing, from 5288.3% in the prior quarter.
- Across five years, EBIT Margin topped out at 1865.62% in Q4 2021 and bottomed at 23682.56% in Q3 2025.
- The 3-year median for EBIT Margin is 3890.32% (2022), against an average of 7442.68%.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 98.77% |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 33.60% |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 1.97% |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 5.74% |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 34.92% |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 20.53% |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -2.87% |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 4.04% |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 13.65% |
| 10 | Pulse Biosciences | 2.09 Bn | 2.01 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -23,682.56% |
| Jun 30, 2022 | -5,288.30% |
| Mar 31, 2022 | -3,890.32% |
| Dec 31, 2021 | -1,865.62% |
| Sep 30, 2021 | -2,486.59% |